BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21359911)

  • 1. Histology-driven chemotherapy in soft tissue sarcomas.
    Scurr M
    Curr Treat Options Oncol; 2011 Mar; 12(1):32-45. PubMed ID: 21359911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
    Italiano A; Toulmonde M; Bui-Nguyen B
    Bull Cancer; 2010 Jun; 97(6):679-86. PubMed ID: 20483708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas.
    Casali PG
    Ann Oncol; 2012 Sep; 23 Suppl 10():x167-9. PubMed ID: 22987955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of chemotherapy in the management of soft tissue sarcomas.
    Krikelis D; Judson I
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):249-60. PubMed ID: 20132000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical treatment of soft tissue sarcomas based on the histological subtype].
    Pápai Z
    Magy Onkol; 2014 Mar; 58(1):53-8. PubMed ID: 24712007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histology-Specific Chemotherapy in Soft-Tissue Sarcomas].
    Kobayashi E; Kawai A
    Gan To Kagaku Ryoho; 2017 Jun; 44(6):468-472. PubMed ID: 28698435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating soft tissue sarcomas with adjuvant chemotherapy.
    Patrikidou A; Domont J; Cioffi A; Le Cesne A
    Curr Treat Options Oncol; 2011 Mar; 12(1):21-31. PubMed ID: 21384115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histology-driven chemotherapy of soft-tissue sarcoma.
    Eriksson M
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii270-6. PubMed ID: 20943627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic management strategies for metastatic soft tissue sarcoma.
    Movva S; Verschraegen C
    Drugs; 2011 Nov; 71(16):2115-29. PubMed ID: 22035513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
    Schöffski P; Dumez H; Wolter P; Stefan C; Wozniak A; Jimeno J; Van Oosterom AT
    Expert Opin Pharmacother; 2008 Jun; 9(9):1609-18. PubMed ID: 18518789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
    Hartmann JT; Patel S
    Drugs; 2005; 65(2):167-78. PubMed ID: 15631540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
    Ray-Coquard I; Rizzo E; Blay JY; Casali P; Judson I; Hansen AK; Lindner LH; Dei Tos AP; Gelderblom H; Marreaud S; Litière S; Rutkowski P; Hohenberger P; Gronchi A; van der Graaf WT
    Gynecol Oncol; 2016 Jul; 142(1):95-101. PubMed ID: 27208537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic strategies for soft tissue sarcomas.
    von Mehren M
    Curr Treat Options Oncol; 2003 Dec; 4(6):441-51. PubMed ID: 14585225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
    Ryan CW; Desai J
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current management options for liposarcoma and challenges for the future.
    Kollár A; Benson C
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):297-306. PubMed ID: 24397249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
    Kopp HG; Patel S; Brücher B; Hartmann JT
    Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin therapy for sarcomas.
    Casali PG; Sanfilippo R; D'Incalci M
    Curr Opin Oncol; 2010 Jul; 22(4):342-6. PubMed ID: 20489618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of treating by histological subtype in advanced soft tissue sarcoma.
    Martín Broto J; Le Cesne A; Reichardt P
    Future Oncol; 2017 Jan; 13(1s):23-31. PubMed ID: 27918201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.